Bottom line
XLV vs PRHSX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 80% by weight.
But PRHSX is far broader, holding 279 positions to 65 for XLV, so beyond the top names it adds exposure XLV doesn't have.
XLV is cheaper at 0.08% vs 0.83% — a difference of $75 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
XLV vs PRHSX side by side
| XLV | PRHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.83% |
| Annual cost per $10k | $8 | $83 |
| 10-yr cost on $10k (prospectus) | $103 | $1,025 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +17.7% |
| 5-yr return (annualized) | +8.1% | +4.2% |
| 10-yr return (annualized) | +9.8% | +9.1% |
| Best quarter | +14.5% | +23.5% |
| Worst quarter | −12.7% | −15.8% |
| Net assets (fund) | $40.6B | $11.9B |
| Number of holdings | 65 | 279 |
| Portfolio turnover | 2% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | PRHSX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +17.7% | −3.2% |
| 2024 | +2.5% | +1.8% | +0.7% |
| 2023 | +2.0% | +3.1% | −1.1% |
| 2022 | −2.1% | −12.2% | +10.1% |
| 2021 | +25.9% | +13.3% | +12.6% |
| 2020 | +13.3% | +30.1% | −16.9% |
| 2019 | +20.7% | +29.1% | −8.5% |
| 2018 | +6.3% | +1.2% | +5.1% |
| 2017 | +21.7% | +28.0% | −6.3% |
| 2016 | −2.8% | −10.4% | +7.5% |
Source: Fund prospectus bar charts
Holdings overlap
17 of XLV's top 25 holdings also appear in PRHSX's top 25.
| Holding | XLV | PRHSX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 14.28% |
| Johnson & Johnson | 10.64% | 6.63% |
| AbbVie Inc | 7.74% | 5.10% |
| UnitedHealth Group Inc | 6.57% | 5.99% |
| Merck & Co Inc | 5.52% | 4.01% |
| Amgen Inc | 3.40% | 1.82% |
| Thermo Fisher Scientific Inc | 3.24% | 2.52% |
| Abbott Laboratories | 2.75% | 1.89% |
| Gilead Sciences Inc | 2.73% | 2.82% |
| Intuitive Surgical Inc | 2.45% | 1.87% |
| CVS Health Corp | 2.30% | 0.94% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.28% |
| Danaher Corp | 2.09% | 1.43% |
| Bristol-Myers Squibb Co | 2.05% | 2.11% |
| Stryker Corp | 1.89% | 1.78% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between XLV and PRHSX?
Which is cheaper, XLV or PRHSX?
Should I own both XLV and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.